A novel method for the stereospecificsynthesis of 1,5-disubstituted tetrazoles from ketoximes via the Beckmann rearrangement was developed using diphenyl phosphorazidate (DPPA) as both the oxime activator and azide source. Various ketoximes were transformed into the corresponding 1,5-disubstituted tetrazoles with exclusive trans-group migration and no E-Z isomerization of the ketoxime. This method
[EN] N-CYCLYL-3 - (CYCLYLCARBONYLAMINOMETHYL) BENZAMIDE DERIVATIVES AS RHO KINASE INHIBITORS<br/>[FR] DÉRIVÉS DE N-CYCLYL-3-(CYCLYLCARBONYLAMINOMÉTHYL)BENZAMIDE EN TANT QU'INHIBITEURS DE LA RHO KINASE
申请人:BOEHRINGER INGELHEIM INT
公开号:WO2012006203A1
公开(公告)日:2012-01-12
The present invention relates to compounds of formula (I) : and pharmaceutically acceptable salts thereof, wherein R1and R2 are various ring systems. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of Rho Kinase mediated diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
An efficient conversion of carbonyl compounds (aldehydes and ketones) to nitrile, tetrazole, and urea was developed with the use of a POCl3 and sodium azide mixture using a convergent and microwave method. This is the first report on the direct conversion of ketone to urea. The synthesized compounds were characterized by 1H NMR, 13C NMR, mass and IR spectroscopies and were found to be in agreement
通过使用会聚和微波方法使用POCl 3和叠氮化钠混合物,开发了将羰基化合物(醛和酮)有效转化为腈,四唑和尿素的方法。这是有关酮直接转化为尿素的第一份报告。合成的化合物通过1 H NMR,13 C NMR,质谱和IR光谱进行表征,并且发现与报道的化合物一致。
Gold-Catalyzed Synthesis of Tetrazoles from Alkynes by CC Bond Cleavage
作者:Morgane Gaydou、Antonio M. Echavarren
DOI:10.1002/anie.201308076
日期:2013.12.9
Golden duality: Tetrazoles are formed by the reaction of alkynes with TMSN3 (TMS=trimethylsilyl) in the presence of iPrOH and the gold(I) catalyst [JohnPhosAu(MeCN)]SbF6. In this transformation gold plays a dual role, first activating the alkyne and then generating a Brønsted acid in situ.
The present invention relates to apoptosis signal-regulating kinase 1 (“ASK1”) inhibiting compounds of the formula (I); wherein the variables are as defined herein. The invention also relates to pharmaceutical compositions, kits and articles of manufacture comprising such compounds; methods and intermediates useful for making the compounds; and methods of using said compounds.